Retraction Note: TRIB2 confers resistance to anti-cancer therapy by activating the serine/threonine protein kinase AKT

Richard Hill^{1

2

3}, Patricia A Madureira², Bibiana Ferreira², Inês Baptista², Susana Machado², Laura Colaҫo², Marta Dos Santos², Ningshu Liu⁴, Ana Dopazo⁵, Selma Ugurel⁶, Angyal Adrienn⁷, Endre Kiss-Toth⁷, Murat Isbilen⁸, Ali O Gure⁸, Wolfgang Link^{9

10

11}

Affiliations

¹ Department of Biomedical Sciences and Medicine (DCBM), University of Algarve, Campus de Gambelas, Faro, 8005-139, Portugal.
² Centre for Biomedical Research (CBMR), University of Algarve, Campus de Gambelas, Faro, 8005-139, Portugal.
³ Brain Tumour Research Centre, Institute of Biomedical and Biomolecular Sciences, University of Portsmouth, PO1 2DT, Portsmouth, UK.
⁴ Bayer AG, Drug Discovery Oncology Research, Berlin, D-13342, Germany.
⁵ Genomics Unit, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, 28029, Spain.
⁶ Department of Dermatology, University Hospital Essen, Essen, 45147, Germany.
⁷ Department of Cardiovascular Science, University of Sheffield, Sheffield, S10 2RX, UK.
⁸ Department of Molecular Biology and Genetics, Bilkent University, Ankara, 06533, Turkey.
⁹ Department of Biomedical Sciences and Medicine (DCBM), University of Algarve, Campus de Gambelas, Faro, 8005-139, Portugal. walink@ualg.pt.
¹⁰ Centre for Biomedical Research (CBMR), University of Algarve, Campus de Gambelas, Faro, 8005-139, Portugal. walink@ualg.pt.
¹¹ Algarve Biomedical Center (ABC), University of Algarve, Campus de Gambelas, Faro, 8005-139, Portugal. walink@ualg.pt.

Richard Hill et al. Nat Commun. 2023.

. 2023 Jul 19;14(1):4341.

doi: 10.1038/s41467-023-40050-1.

¹ Department of Biomedical Sciences and Medicine (DCBM), University of Algarve, Campus de Gambelas, Faro, 8005-139, Portugal.
² Centre for Biomedical Research (CBMR), University of Algarve, Campus de Gambelas, Faro, 8005-139, Portugal.
³ Brain Tumour Research Centre, Institute of Biomedical and Biomolecular Sciences, University of Portsmouth, PO1 2DT, Portsmouth, UK.
⁴ Bayer AG, Drug Discovery Oncology Research, Berlin, D-13342, Germany.
⁵ Genomics Unit, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, 28029, Spain.
⁶ Department of Dermatology, University Hospital Essen, Essen, 45147, Germany.
⁷ Department of Cardiovascular Science, University of Sheffield, Sheffield, S10 2RX, UK.
⁸ Department of Molecular Biology and Genetics, Bilkent University, Ankara, 06533, Turkey.
⁹ Department of Biomedical Sciences and Medicine (DCBM), University of Algarve, Campus de Gambelas, Faro, 8005-139, Portugal. walink@ualg.pt.
¹⁰ Centre for Biomedical Research (CBMR), University of Algarve, Campus de Gambelas, Faro, 8005-139, Portugal. walink@ualg.pt.
¹¹ Algarve Biomedical Center (ABC), University of Algarve, Campus de Gambelas, Faro, 8005-139, Portugal. walink@ualg.pt.

No abstract available

Retraction of

TRIB2 confers resistance to anti-cancer therapy by activating the serine/threonine protein kinase AKT.
Hill R, Madureira PA, Ferreira B, Baptista I, Machado S, Colaço L, Dos Santos M, Liu N, Dopazo A, Ugurel S, Adrienn A, Kiss-Toth E, Isbilen M, Gure AO, Link W. Hill R, et al. Nat Commun. 2017 Mar 9;8:14687. doi: 10.1038/ncomms14687. Nat Commun. 2017. Retraction in: Nat Commun. 2023 Jul 19;14(1):4341. doi: 10.1038/s41467-023-40050-1. PMID: 28276427 Free PMC article. Retracted.